Advanced Cancer Clinical Trial
Official title:
An Open-label, Multi-centre, Single-dose Clinical Trial to Assess the Pharmacokinetic (PK) Properties and Tolerability of a Single Oromucosal Dose of 6 Sprays of Sativex® in Patients With Advanced Cancer Currently on Background Step III Opioid Therapy
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oromucosal dose of Sativex in subjects with advanced cancer currently on background Step III opioid therapy.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | October 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
For inclusion in the trial subjects must fulfil ALL of the following criteria: - The subject is aged =18 years. - The subject has advanced cancer for which there is no known curative therapy. - The subject has a clinical diagnosis of cancer related pain, is currently taking Step III opioid therapy and is willing to continue on their current dosing regimen throughout the Inpatient/Treatment Period of the trial. - The subject is willing and able to give written informed consent. - The subject is willing and able to comply with all trial requirements. The subject may not enter the trial if ANY of the following apply: - The subject is receiving intrathecal opioids via pump mechanism. - The subject is currently using or has used cannabis or cannabinoid based medications within 30 days of trial entry and is unwilling to abstain for the duration of the trial. - The subject has any known or suspected history of a substance abuse/dependence disorder (including opiate abuse/dependence prior to the diagnosis of cancer); current heavy alcohol consumption (more than 60 grams of pure alcohol per day for men, and more than 40 grams of pure alcohol per day for women) and unwilling to abstain from alcohol for 24 hours prior to and during trial visits; current use of an illicit drug or current non prescribed use of any prescription drug. - The subject has a history of epilepsy as evidenced by one or more seizures in the last 12 months. - The subject has any known or suspected history or family history of schizophrenia, or other psychotic illness, history of severe personality disorder or other severe significant psychiatric disorder other than depression associated with the underlying condition. - The subject has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP. - The subject has significant cardiac disease, or has a cardiac disorder that in the opinion of the investigator would put the subject at risk of a clinically relevant arrhythmia or myocardial infarction, or has a secondary or tertiary atrioventricular block, or evidence of clinically significant cardiac disease on ECG at the Screening Visit. - The subject has significantly impaired renal function as evidenced by a creatinine clearance (based on measured serum creatinine level) lower than 40 mL/min at Visit 1. - The subject has significantly impaired hepatic function at Visit 1 (alanine aminotransferase [ALT] >5 upper limit of normal (ULN) or total bilirubin [TBL] > 2 ULN). If the ALT or aspartate aminotransferase [AST] >3 ULN and the TBL >2 ULN [or international normalized ratio [INR] >1.5]) this subject must not enter the trial. - The subject is a female of childbearing potential, or a male patient whose partner is of childbearing potential, is unwilling to ensure that they and/or their partner use a highly effective method of contraception, including female sterilization (ie, documented bilateral tubal ligation), male sterilization, established use of hormonal methods of contraception (oral, implanted or transdermal), an intrauterine device or intrauterine system, or true abstinence. - Female subject who is pregnant, lactating or planning pregnancy during the course of the trial and for 3 months thereafter. - The subject has received a non approved IMP within 30 days or 5 times the half-life of the IMP (whichever is greater) prior to the Screening Visit. - The subject has any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial, or may influence the result of the trial, or the patient's ability to participate in the trial. - The subject was previously enrolled in the current trial or any other Sativex clinical trial for cancer pain. - The subject is unwilling to abstain from the consumption of grapefruit products during the week prior to and throughout the Inpatient/Treatment period. |
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
GW Pharmaceuticals Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacokinetic endpoints of the analyte delta 9-tetrahydrocannabinol (THC). | • Mean maximum plasma concentration (Cmax) of THC. | 0-48 hours post-dose | No |
Primary | Pharmacokinetic endpoints of the analyte THC. | • Mean area under the concentration-time curve calculated from time zero to the last observable concentration at time t (AUC(0-t)) of THC. | 0-48 hours post-dose | No |
Primary | Pharmacokinetic endpoints of the analyte THC. | • Mean area under the concentration-time curve from time zero to infinity (AUC(0-8)) of THC. | 0-48 hours post-dose | No |
Primary | Pharmacokinetic endpoints of the analyte 11-hydroxy-delta 9-tetrahydrocannabinol (11-OH-THC). | • Mean Cmax of 11-OH-THC. | 0-48 hours post-dose | No |
Primary | Pharmacokinetic endpoints of the analyte 11-OH-THC. | • Mean AUC(0-t)) of 11-OH-THC. | 0-48 hours post-dose | No |
Primary | Pharmacokinetic endpoints of the analyte 11-OH-THC. | • Mean AUC(0-8) of 11-OH-THC. | 0-48 hours post-dose | No |
Primary | Pharmacokinetic endpoints of the analyte 11-carboxy-delta 9-tetrahydrocannabinol (11-COOH-THC). | • Mean Cmax of 11-COOH-THC. | 0-48 hours post-dose | No |
Primary | Pharmacokinetic endpoints of the analyte 11-COOH-THC. | • Mean AUC(0-t)) of 11-COOH-THC. | 0-48 hours post-dose | No |
Primary | Pharmacokinetic endpoints of the analyte 11-COOH-THC. | • Mean AUC(0-8) of 11-COOH-THC. | 0-48 hours post dose | No |
Primary | Pharmacokinetic endpoints of the analyte cannabidiol (CBD). | • Mean Cmax of CBD. | 0-48 hours | No |
Primary | Pharmacokinetic endpoints of the analyte CBD. | • Mean AUC(0-t) of CBD. | 0-48 hours | No |
Primary | Pharmacokinetic endpoints of the analyte CBD. | • Mean AUC(0-8) of CBD. | 0-48 hours | No |
Primary | Pharmacokinetic endpoints of the analyte 6-hydroxy-cannabidiol (6-OH-CBD). | • Mean Cmax of 6-OH-CBD. | 0-48 hours. | No |
Primary | Pharmacokinetic endpoints of the analyte 6-OH-CBD. | • Mean AUC(0-t) of 6-OH-CBD. | 0-48 hours | No |
Primary | Pharmacokinetic endpoints of the analyte 6-OH-CBD. | • Mean AUC(0-8) of 6-OH-CBD. | 0-48 hours. | No |
Primary | Pharmacokinetic endpoints of the analyte 7-hydroxy-cannabidiol (7-OH-CBD). | • Mean Cmax of 7-OH-CBD. | 0-48 hours | No |
Primary | Pharmacokinetic endpoints of the analyte 7-OH-CBD. | • Mean AUC(0-t) of 7-OH-CBD. | 0-48 hours | No |
Primary | Pharmacokinetic endpoints of the analyte 7-OH-CBD. | • Mean AUC(0-8) of 7-OH-CBD. | 0-48 hours | No |
Primary | Pharmacokinetic endpoints of the analyte 7-carboxy-cannabidiol (7-COOH-CBD). | • Mean Cmax of 7-COOH-CBD. | 0-48 hours | No |
Primary | Pharmacokinetic endpoints of the analyte 7-COOH-CBD. | • Mean AUC(0-t) of 7-COOH-CBD. | 0-48 hours | No |
Primary | Pharmacokinetic endpoints of the analyte 7-COOH-CBD. | • Mean AUC(0-8) of 7-COOH-CBD. | 0-48 hours | No |
Secondary | Pharmacokinetic endpoints of the analyte THC. | • Mean half-life (t1/2) of THC. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte THC. | • Mean time to maximum plasma concentration (tmax) of THC. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte THC. | • Mean apparent clearance of drug from plasma after extravascular administration (CL/F) of THC. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte THC. | • Mean apparent volume of distribution (Vd/F) of THC. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 11-OH-THC. | • Mean t1/2 of 11-OH-THC. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 11-OH-THC. | • Mean tmax of 11-OH-THC. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 11-COOH-THC. | • Mean t1/2 of 11-COOH-THC. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 11-COOH-THC. | • Mean tmax of 11-COOH-THC. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte CBD. | • Mean t1/2 of CBD. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte CBD. | • Mean tmax of CBD. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte CBD. | • Mean CL/F of CBD. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte CBD. | • Mean Vd/F of CBD. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 6-OH-CBD. | • Mean t1/2 of 6-OH-CBD. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 6-OH-CBD. | • Mean tmax of 6-OH-CBD. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 7-OH-CBD. | • Mean t1/2 of 7-OH-CBD. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 7-OH-CBD. | • Mean tmax of 7-OH-CBD. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 7-COOH-CBD. | • Mean t1/2 of 7-COOH-CBD. | 0-48 hours post-dose | No |
Secondary | Pharmacokinetic endpoints of the analyte 7-COOH-CBD. | • Mean tmax of 7-COOH-CBD. | 0-48 hours post-dose | No |
Secondary | The incidence of adverse events as a measure of subject safety. | The number of subjects who experienced an adverse event during the study is presented. The time-frame for adverse event reporting was from screening to follow-up visit. | From screening to follow-up (a maximum of 19 days). | Yes |
Secondary | The number of subjects with a clinically significant change in physical and oral examination results, relative to pre-treatment baseline. | The number of subjects with a change in physical and oral examination results indicative of an adverse event, relative to the pre-treatment baseline, is presented. | From screening to follow-up (a maximum of 19 days) | Yes |
Secondary | The number of subjects with a clinically significant change in in 12-lead ECG (electrocardiogram) results, relative to pre-treatment baseline. | The number of subjects with a change in ECG results indicative of an adverse event, relative to the pre-treatment baseline, is presented. | From screening to follow-up (a maximum of 19 days) | Yes |
Secondary | The number of subjects with clinically significant changes in laboratory test parameters, relative to pre-treatment baseline. | The number of subjects with clinically significant changes in serum biochemistry, haematology and urinalysis, relative to the pre-treatment baseline, is presented. | From screening to follow-up (a maximum of 19 days) | Yes |
Secondary | The number of subjects with a clinically significant change in vital signs, relative to pre-treatment baseline. | The number of subjects with a clinically significant change in vital signs (supine/sitting blood pressure and pulse rate) indicative of an adverse event relative to the pre-treatment baseline, is presented. | From screening to follow-up (a maximum of 19 days) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A |